CDG Stock Overview
A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Acorda Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.79 |
52 Week High | US$15.90 |
52 Week Low | US$0.79 |
Beta | 1.65 |
11 Month Change | 0% |
3 Month Change | -53.82% |
1 Year Change | -93.28% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -91.74% |
Recent News & Updates
Recent updates
Shareholder Returns
CDG | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -3.0% | -0.1% |
1Y | -93.3% | -19.4% | 2.3% |
Return vs Industry: CDG underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: CDG underperformed the German Market which returned 2.3% over the past year.
Price Volatility
CDG volatility | |
---|---|
CDG Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CDG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CDG's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 102 | Ron Cohen | www.acorda.com |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Acorda Therapeutics, Inc. Fundamentals Summary
CDG fundamental statistics | |
---|---|
Market cap | €277.62k |
Earnings (TTM) | -€245.33m |
Revenue (TTM) | €107.72m |
0.0x
P/S Ratio0.0x
P/E RatioIs CDG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CDG income statement (TTM) | |
---|---|
Revenue | US$115.66m |
Cost of Revenue | US$20.48m |
Gross Profit | US$95.19m |
Other Expenses | US$358.61m |
Earnings | -US$263.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -212.08 |
Gross Margin | 82.30% |
Net Profit Margin | -227.75% |
Debt/Equity Ratio | -103.1% |
How did CDG perform over the long term?
See historical performance and comparison